Johnson & Johnson (JNJ) investor relations material

Business performance and growth outlook

• Achieved $15.4 billion in Q1 revenue, marking the fourth consecutive quarter above $15 billion.

• Operational growth reached 17% in the U.S. excluding STELARA, with 22% growth in the U.S.

• Ten products delivered double-digit growth in Q1, with strong momentum projected into 2026 and beyond.

• Targeting 5%-7% compound annual growth rate over the next five years, aiming for the upper end.

• Significant growth expected to be highlighted at the upcoming enterprise business review.

Key product launches and market dynamics

• TREMFYA posted 64% growth in Q1, leading new patient starts in IBD and showing strong differentiation in perianal fistulizing Crohn's disease.

• ICOTYDE launch saw rapid uptake, with 4,500 prescribers and high intent to prescribe, especially among systemic-naive patients.

• INLEXZO achieved 82% complete remission rates in a niche bladder cancer population, with rapid provider adoption post J-code.

• RYBREVANT and ERLEADA are gaining traction in oncology, with ERLEADA's PROTEUS data seen as practice-changing.

Pipeline and innovation highlights

• JNJ-4804, a co-antibody targeting IL-23 and TNF, is positioned for refractory IBD patients, representing a 1 million patient opportunity.

• Nipocalimab is advancing in multiple indications, including MG, wAIHA, lupus, and Sjögren's, with $5 billion+ potential.

• Tri-specific and in vivo CAR T programs are progressing, aiming to improve outcomes in multiple myeloma and other cancers.

• Prostate cancer pipeline expanded with Halda Therapeutics acquisition and RIPTAC technology, targeting curative intent across modalities.